Is anyone else getting “this video is private “ when opening?

You must have dug really hard for that article George!
Thanks for posting!!

AVXL positive write up
https://www.fool.com/amp/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/

Good to see you’re back Nidan… now if we can just get BSC to free up some time and return!

Apparently the company is communicating with the FDA Which is a good thing. Perhaps they discussed approval criteria and wanted additional trail participants and endpoints.
If it results in Rett approval next year, a few months delay will be well worth it.
I still believe that there is a lot going on behind the scenes. Frustrating for investors, especially for those that haven’t been here for years, and have gotten used to the lack of info and never ending delays.

Hopefully the line will be miles long in a couple years!

“complete the Anavex 2-73 drug trial for Rett Syndrome. Annelise completed a 12 week double blind trial and a 48 week Open label. “

She was taking A2-73 for the 48 week study.

THE NATIVES ARE GETTING RESTLESS! ??

If it’s any comfort to AVXL investors on the snails pace of the trials, NWBO’s DCVax finally completed a 13 year p3 trial and has been waiting for TLD over a year now from data lock!

Hopefully, Missling was smart to hire two former FDA higher ups that might still have some connections there.

Same thing crossed my mind when I read it. That was nine years ago!! And here we are still waiting!

A good review of the Cantor conference from a poster on another MB…thanks AM ST!


“”The conference reiterates what the company has been presenting in the past:

1) In all trials to date, they see a response in all patients.

2) The response is dose dependent.

3) They can see in the mRNA data the different responses - i.e., placebo, mid-dose, high-dose.

4) They see in all cases a difference between the response in those who have the "full sigma-1" gene and those that don't. More than 80% of the population has the full gene and people with it respond better. Those who who don't have the gene respond less. But in either case, all patients respond and the response can be differentiated even in those without the full sigma-1 gene to be above the response to the placebo.

Essentially, the above is sufficient to prove that that the drug works - they will get approved.

https://wsw.com/webcast/cantor12/avxl.ob/25”

The good thing about the TV ads, there won’t be 40 seconds of side affects at the end!!

It is naive to think that the extreme lockdowns in Australia aren’t affecting the recruitment.

I’m actually happy to see the market reward a one trick pony, with questionable results.
If their SP increases dollars almost daily, just think of what might happen to AVXL in a few months or a couple years when approvals and revenue start flowing.

You never know. I do miss his posts though.

Don’t think so. He is a hard core long.

Any know what happened to Nidan?

From another MB, but thought it is relevant here….
“ On the subject of patents, it's rare that companies PR their patents. The companies who do typically hype everything they do, generally they're on the Pinks. Both the FDA and SEC deplore hype, so it's probably best that they allow investors to discover what they're doing. Much the same is often true when they file IND's, etc. ”

Unfortunately, whether people want to accept it or not, AVXL is still tied to the other AD baby bios share price wise.

Nidan? Are you still with us? It’s been awhile.

Perhaps the receptor is more responsive when intermittently activated rather than a constant supply.

Every run up is sold off. Hard for the sp to gain any traction.
Half of the “LONGS “ here sell on any pops.

https://seekingalpha.com/article/4452448-anavex-life-sciences-still-room-to-run?source=ios-messages

All parties involved in SAVA will be getting a big payday if the can keep the SP above $120 for 20 days!
Interesting reason why the CEO and analysts are pushing SAVA so hard...
10Q):
"If the Company were to exceed a $5 billion market capitalization for no less than 20 consecutive trading days, and conditions noted above for payment are met, all Plan milestones would be deemed achieved, in which case total cash bonus awards would range from a minimum of $137.4 million up to a hypothetical maximum of $322.3 million."

Thanks Guzzi,

Any idea who Neil Rebowe/Anavex Life Science and Jeffrey Sprouse/Anavex Life Science are? Both listed ar authors of the Fragile X Peer paper.

Good point boi. It’s like turning around a battle ship, its long , slow progress but it looks like things are finally going in the right direction.

Thanks Bourbon,good to hear!

Biostockclub, are you still out there?? It’s been a couple months. I miss reading your posts.

Well said boi, We have to trust that Dr.M knows what he is doing. I’m confident that he wants the fastest path to approvals and commercialization as every poster on this MB

Thx Investor. The link is already expired

I agree. It sounded a little too bold for Dr M to say something in those words.

Does anyone know if there will be a replay of the chat?

Did anyone else here listen to the chat?
Maybe that was just his interpretation.

From a poster on ST that just watched the BTIG chat-
Missling-“we are on the way for an FDA approval for Rett very soon and PD soon.
Alzheimer’s next year “
Don’t shoot the messenger

I said it before the June 6 Biogen approval and I still believe that the Adu approval will not benefit AVXL.
Now we have competition coming out of the woodwork bogging down the FDA. As WS clearly doesn’t understand the science, Anavex might get lost in the crowd even if our MOA is different and superior.

PS..... save it ffrol, I don’t need your cookie cutter response about someone trying to steal my shares!

Where are the gaps? They might as well take them out today so we can finish green!

From $3 to $900 in one year on a drug that missed its endpoints. That’s something serious pumping.
A good example of the corruption on ws, but hey, I wouldn’t complain if it happened to AVXL.

Another GA AVXL long here too

There is also the TGA wildcard. It’s entirely possible that the Ausralians grant an early approval based on years of data.